Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective study

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 492-505

  Rizos, Christos V ^a   Milionis, Haralampos J ^a   Kostapanos, Michael S ^a   Florentin, Matilda ^a   Kostara, Christina E ^a   Elisaf, Moses S ^a   Liberopoulos, Evangelos N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Angiotensin II receptor antagonists; Glucose metabolism; PPAR ; Rosuvastatin; Statins; Telmisartan

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; IRBESARTAN; OLMESARTAN; ROSUVASTATIN; TELMISARTAN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GREECE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; FASTING; FEMALE; FLUOROBENZENES; GREECE; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; IMIDAZOLES; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES; TETRAZOLES;

EID: 77951921451     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.018     Document Type: Article

References (48)

1. Liberopoulos EN, Mikhailidis DP, Elisaf MS Diagnosis and management of the metabolic syndrome in obesity. Obes Rev. 2005, 6:283-296.
2. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003, 92:152-160. STELLAR Study Group.
3. Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther. 2007, 29:1403-1414.
4. Kostapanos MS, Milionis HJ, Elisaf MS An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther. 2008, 13:157-174.
5. Sasaki J, Iwashita M, Kono S Statins: Beneficial or adverse for glucose metabolism. J Atheroscler Thromb. 2006, 13:123-129.
6. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial. Lancet. 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
7. Sabatine MS, Wiviott SD, Morrow DA, et al. High dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 substudy. Circulation 2004, 110(Suppl):S834. Abstract.
8. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. lancet. 2003, 361:1149-1158. ASCOT Investigators.
9. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-2207. JUPITER Study Group.
10. Elliott WJ, Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis [published correction appears in Lancet.. 2007;369:1518]. Lancet. 2007, 369:201-207.
11. Cheung BM, Cheung GT, Lauder IJ, et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006, 20:37-43.
12. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004, 43:993-1002.
13. Semple RK, Chatterjee VK, O'Rahilly S PPAR gamma and human metabolic disease. J Clin Invest. 2006, 116:581-589.
14. Rizos CV, Elisaf MS, Liberopoulos EN Are the pleiotropic effects of telmisartan clinically relevant?. Curr Pharm Des. 2009, 15:2815-2832.
15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections appear in Circulation. 2005;112: e297 and 2005;112:e298]. Circulation. 2005, 112:2735-2752. American Heart Association and National Heart, Lung, and Blood Institute.
16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
17. Sacks FM, Svetkey LP, Vollmer WM, et al. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001, 344:3-10. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet.
18. Stergiou GS, Tzamouranis D, Protogerou A, et al. Validation of the Microlife Watch BP Office professional device for office blood pressure measurement according to the International protocol. Blood Press Monit. 2008, 13:299-303.
19. Wallace TM, Levy JC, Matthews DR Use and abuse of HOMA modeling. Diabetes Care. 2004, 27:1487-1495.
20. Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18:499-502.
21. Derosa G, Cicero AF, D'Angelo A, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res. 2006, 29:849-856.
22. Kostapanos MS, Milionis HJ, Agouridis A, et al. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidemic patients with impaired fasting glucose. Int J Clin Pract. 2009, 63:1308-1313.
23. Swinscow TD, Campbell MJ Summary statistics for quantitative and binary data. Statistics at Square One 2002, 12-17. BMJ Books, London, UK. 10th ed.
24. Pallant J Descriptive statistics. SPSS Survival Manual 2001, 54-59. Open University Press, Buckingham, UK.
25. Swinscow TD, Campbell MJ The t tests. Statistics at Square One 2002, 71-74. BMJ Books, London, UK. 10th ed.
26. Campbell MJ Multiple linear regression. Statistics at Square Two 2001, 22-23. BMJ Books, London, UK.
27. Swinscow TD, Campbell MJ Correlation and regression. Statistics at Square One 2002, 111-115. BMJ Books, London, UK. 10th ed.
28. Song Y, Manson JE, Tinker L, et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: The Women's Health Initiative Observational Study. Diabetes Care. 2007, 30:1747-1752.
29. Hanley AJ, Williams K, Gonzalez C, et al. Prediction of type 2 diabetes using simple measures of insulin resistance: Combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study [published correction appears in Diabetes. 2003;52:1306]. Diabetes. 2003, 52:463-469. San Antonio Heart Study, Mexico City Diabetes Study, and Insulin Resistance Atherosclerosis Study.
30. Perkins JM, Davis SN The reninangiotensin-aldosterone system: A pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes. 2008, 15:147-152.
31. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001, 103:357-362.
32. Chamberlain LH Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001, 507:357-361.
33. Yada T, Nakata M, Shiraishi T, Kakei M Inhibition by simvastatin, but not pravastatin, of glucoseinduced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999, 126:1205-1213.
34. Ichikawa Y Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med. 2007, 46:1331-1336.
35. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005, 4:6.
36. Dankner R, Chetrit A, Shanik MH, et al. Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: A preliminary report. Diabetes Care. 2009, 32:1464-1466.
37. Landmesser U, Drexler H Effect of angiotensin II type 1 receptor antagonism on endothelial function: Role of bradykinin and nitric oxide. J Hypertens Suppl. 2006, 24:S39-S43.
38. Ceriello A, Motz E Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24:816-823.
39. Adrogué HJ, Madias NE Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007, 356:1966-1978.
40. Tabák AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet. 2009, 373:2215-2221.
41. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358:1547-1559. ONTARGET Investigators.
42. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. [published correction appears in Lancet. 2008;372:1384]. Lancet. 2008, 372:1174-1183. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND).
43. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008, 359:1225-1237. PRoFESS Study Group.
44. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004, 27:457-464.
45. Inoue T, Morooka T, Moroe K, et al. Effect of telmisartan on cholesterol levels in patients with hypertension-Saga Telmisartan Aggressive Research (STAR). Horm Metab Res. 2007, 39:372-376.
46. Jong MC, Hofker MH, Havekes LM Role of ApoCs in lipoprotein metabolism: Functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999, 19:472-484.
47. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009, 373:1175-1182. JUPITER Trial Study Group.
48. Porto I, Di Vito L, De Maria GL, et al. Comparison of the effects of ramipril versus telmisartan on highsensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome. Am J Cardiol. 2009, 103:1500-1505.